HRP20160034T1 - Humanizirani antagonisti anti-beta7 i njihove uporabe - Google Patents

Humanizirani antagonisti anti-beta7 i njihove uporabe Download PDF

Info

Publication number
HRP20160034T1
HRP20160034T1 HRP20160034TT HRP20160034T HRP20160034T1 HR P20160034 T1 HRP20160034 T1 HR P20160034T1 HR P20160034T T HRP20160034T T HR P20160034TT HR P20160034 T HRP20160034 T HR P20160034T HR P20160034 T1 HRP20160034 T1 HR P20160034T1
Authority
HR
Croatia
Prior art keywords
hvr
seq
host cell
humanized anti
nucleic acid
Prior art date
Application number
HRP20160034TT
Other languages
English (en)
Inventor
Mark S. Dennis
Sherman Fong
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of HRP20160034T1 publication Critical patent/HRP20160034T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Surgery (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (16)

1. Izolirana nukleinska kiselina, naznačena time, da kodira humanizirano protutijelo anti-beta7, te obuhvaća: HVR-L1, HVR-L2, HVR-L3, HVR-H1, HVR-H2 i HVR-H3, pri čemu svaki po redu sadrži RASESVDDLLH (SEQ ID NO:9), KYASQSIS (SEQ ID NO:2), QQGNSLPNT (SEQ ID NO:3), GFFITNNYWG (SEQ ID NO:4), GYISYSGSTSYNPSLKS (SEQ ID NO:5), i ARTGSSGYFDF (SEQ ID NO:64).
2. Izolirana nukleinska kiselina, naznačena time, da kodira humanizirano protutijelo anti-beta7, te obuhvaća: HVR-L1, HVR-L2, HVR-L3, HVR-H1, HVR-H2 i HVR-H3, pri čemu svaki po redu sadrži RASESVDDLLH (SEQ ID NO:9), KYASQSIS (SEQ ID NO:2), QQGNSLPNT (SEQ ID NO:3), GFFITNNYWG (SEQ ID NO:4), GYISYSGSTSYNPSLKS (SEQ ID NO:5), i MTGSSGYFDF (SEQ ID NO:6).
3. Izolirana nukleinska kiselina, naznačena time, da kodira humanizirano protutijelo anti-beta7, te obuhvaća: HVR-L1, HVR-L2, HVR-L3, HVR-H1, HVR-H2 i HVR-H3, pri čemu svaki po redu sadrži RASESVDDLLH (SEQ ID NO:9), KYASQSIS (SEQ ID NO:2), QQGNSLPNT (SEQ ID NO:3), GFFITNNYWG (SEQ ID NO:4), GYISYSGSTSYNPSLKS (SEQ ID NO:5), i AMTGSSGYFDF (SEQ ID NO:63).
4. Izolirana nukleinska kiselina, naznačena time, da kodira humanizirano protutijelo anti-beta7, te obuhvaća: HVR-L1, HVR-L2, HVR-L3, HVR-H1, HVR-H2 i HVR-H3, pri čemu svaki po redu sadrži RASESVDDLLH (SEQ ID NO:9), KYASQSIS (SEQ ID NO:2), QQGNSLPNT (SEQ ID NO:3), GFFITNNYWG (SEQ ID NO:4), GYISYSGSTSYNPSLKS (SEQ ID NO:5), i RTGSSGYFDF (SEQ ID NO:66).
5. Izolirana nukleinska kiselina, naznačena time, da kodira humanizirano protutijelo anti-beta7, te obuhvaća: HVR-L1, HVR-L2, HVR-L3, HVR-H1, HVR-H2 i HVR-H3, pri čemu svaki po redu sadrži RASESVDSLLH (SEQ ID NO:7), SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, i SEQ ID NO:64.
6. Izolirana nukleinska kiselina, naznačena time, da kodira humanizirano protutijelo anti-beta7, te obuhvaća: HVR-L1, HVR-L2, HVR-L3, HVR-H1, HVR-H2 i HVR-H3, pri čemu svaki po redu sadrži RASESVDSLLH (SEQ ID NO:7), SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, i SEQ ID NO:6.
7. Izolirana nukleinska kiselina, naznačena time, da kodira humanizirano protutijelo anti-beta7, te obuhvaća: HVR-L1, HVR-L2, HVR-L3, HVR-H1, HVR-H2 i HVR-H3, pri čemu svaki po redu sadrži RASESVDTLLH (SEQ ID NO:8), SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, i SEQ ID NO:64.
8. Izolirana nukleinska kiselina, naznačena time, da kodira humanizirano protutijelo anti-beta7, te obuhvaća: HVR-L1, HVR-L2, HVR-L3, HVR-H1, HVR-H2 i HVR-H3, pri čemu svaki po redu sadrži RASESVDTLLH (SEQ ID NO:8), SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, i SEQ ID NO:6.
9. Vektor, naznačen time, da obuhvaća nukleinsku kiselinu prema bilo kojem od zahtjeva 1 do 8.
10. Stanica domaćina, naznačena time, da obuhvaća vektor prema zahtjevu 9.
11. Stanica domaćina prema zahtjevu 10, naznačena time, da stanica domaćina je prokariotska stanica.
12. Stanica domaćina prema zahtjevu 11, naznačena time, da stanica domaćina je E. colli.
13. Stanica domaćina prema zahtjevu 10, naznačena time, da stanica domaćina je eukariotska stanica.
14. Stanica domaćina prema zahtjevu 13, naznačena time, da stanica domaćina je stanica sisavca.
15. Stanica domaćina prema zahtjevu 14, naznačena time, da stanica domaćina je stanica jajnika kineskog hrčka.
16. Postupak izrade humaniziranog protutijela anti-beta7, naznačen time, da spomenuti postupak obuhvaća eksprimiranje rekombinantnog vektora prema zahtjevu 9, u stanici domaćina prema bilo kojem od zahtjeva 10 do 15, i obnavljanje navedenog protutijela.
HRP20160034TT 2004-09-03 2016-01-13 Humanizirani antagonisti anti-beta7 i njihove uporabe HRP20160034T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60737704P 2004-09-03 2004-09-03
EP10177407.3A EP2322556B1 (en) 2004-09-03 2005-09-02 Humanized anti-beta7 antagonists and uses therefor

Publications (1)

Publication Number Publication Date
HRP20160034T1 true HRP20160034T1 (hr) 2016-02-12

Family

ID=36000753

Family Applications (3)

Application Number Title Priority Date Filing Date
HR20120171T HRP20120171T1 (hr) 2004-09-03 2012-02-21 Humanizirani anti-beta 7 antagonisti i njihove uporabe
HRP20160034TT HRP20160034T1 (hr) 2004-09-03 2016-01-13 Humanizirani antagonisti anti-beta7 i njihove uporabe
HRP20181459TT HRP20181459T1 (hr) 2004-09-03 2018-09-12 Humanizirani antagonisti anti-beta7 i njihove uporabe

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HR20120171T HRP20120171T1 (hr) 2004-09-03 2012-02-21 Humanizirani anti-beta 7 antagonisti i njihove uporabe

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20181459TT HRP20181459T1 (hr) 2004-09-03 2018-09-12 Humanizirani antagonisti anti-beta7 i njihove uporabe

Country Status (27)

Country Link
US (10) US7528236B2 (hr)
EP (4) EP2990422B1 (hr)
JP (2) JP5062887B2 (hr)
KR (2) KR101364276B1 (hr)
CN (3) CN101094868B (hr)
AT (1) ATE534668T1 (hr)
AU (1) AU2005279720B2 (hr)
BR (1) BRPI0515602B1 (hr)
CA (1) CA2577678C (hr)
CY (2) CY1112277T1 (hr)
DK (4) DK2322556T3 (hr)
ES (4) ES2377979T3 (hr)
HK (5) HK1188798A1 (hr)
HR (3) HRP20120171T1 (hr)
HU (3) HUE058817T2 (hr)
IL (3) IL181473A (hr)
LT (2) LT2990422T (hr)
MX (3) MX341370B (hr)
NO (3) NO341308B1 (hr)
NZ (2) NZ585628A (hr)
PL (4) PL2990422T3 (hr)
PT (3) PT2990422T (hr)
RS (3) RS57636B1 (hr)
RU (1) RU2453558C2 (hr)
SI (4) SI2322556T1 (hr)
WO (1) WO2006026759A2 (hr)
ZA (1) ZA200701575B (hr)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100591336C (zh) * 2002-11-08 2010-02-24 汪建平 菱角提取物及其使用方法
CA2478458A1 (en) * 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
CN101094868B (zh) 2004-09-03 2013-07-10 健泰科生物技术公司 人源化的抗-β7拮抗剂及其应用
JP2008520717A (ja) * 2004-11-19 2008-06-19 バイオジェン・アイデック・エムエイ・インコーポレイテッド 多発性硬化症についての処置
US10982250B2 (en) * 2006-09-18 2021-04-20 Genentech, Inc. Methods of protein production
US9193790B2 (en) * 2006-12-07 2015-11-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of antagonists of the interaction between HIV GP120 and A4B7 integrin
EP2436781B1 (en) 2007-02-22 2015-10-07 Genentech, Inc. Methods for detecting inflammatory bowel disease
TW200902554A (en) * 2007-05-08 2009-01-16 Genentech Inc Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates
MX2010007515A (es) 2008-01-11 2010-11-12 Chemo Sero Therapeut Res Inst Anticuerpo antiintegrina a9 humana humanizado mejorado.
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
BRPI0910482A2 (pt) * 2008-04-29 2019-09-24 Abbott Lab imunoglobinas de domínio variável duplo e usos das mesmas
WO2009140684A2 (en) * 2008-05-16 2009-11-19 Genentech, Inc. Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7integrin antagonists
NZ589436A (en) * 2008-06-03 2012-12-21 Abbott Lab Dual variable domain immunoglobulins and uses thereof
JP2011523853A (ja) * 2008-06-03 2011-08-25 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリン及びその使用
JP5674654B2 (ja) * 2008-07-08 2015-02-25 アッヴィ・インコーポレイテッド プロスタグランジンｅ２二重可変ドメイン免疫グロブリンおよびその使用
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
BRPI1011389A2 (pt) * 2009-04-17 2018-07-10 Biogen Idec Inc método para tratar a leucemia mielógena aguda (aml) em um paciente
US8399625B1 (en) * 2009-06-25 2013-03-19 ESBATech, an Alcon Biomedical Research Unit, LLC Acceptor framework for CDR grafting
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
UY32870A (es) * 2009-09-01 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
BR112012008833A2 (pt) * 2009-10-15 2015-09-08 Abbott Lab imunoglobulinas de dominio variavel duplo e usos das mesmas
UY32979A (es) * 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2011053665A1 (en) * 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Pcsk9 immunoassay
KR102104197B1 (ko) * 2010-02-23 2020-04-24 제넨테크, 인크. 난소암의 치료를 위한 항혈관신생 요법
WO2011127519A1 (en) * 2010-04-15 2011-10-20 Vegenics Pty Limited Combination treatment with vegf-c antagonists
CN103038257A (zh) 2010-04-16 2013-04-10 比奥根艾迪克Ma公司 抗vla-4抗体
US8735546B2 (en) 2010-08-03 2014-05-27 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
CA2809433A1 (en) 2010-08-26 2012-03-01 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
TW201241180A (en) * 2010-11-02 2012-10-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
MY189494A (en) * 2011-03-31 2022-02-16 Genentech Inc Methods of administering beta7 integrin antagonists
KR101884406B1 (ko) 2011-05-02 2018-08-02 밀레니엄 파머슈티컬스 인코퍼레이티드 항-α4β7 항체에 대한 제형
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
US9120870B2 (en) 2011-12-30 2015-09-01 Abbvie Inc. Dual specific binding proteins directed against IL-13 and IL-17
WO2013126595A1 (en) * 2012-02-21 2013-08-29 Massachusetts Eye And Ear Infirmary Methods for treating corneal and conjunctival inflammation and inflammatory disorders
LT2825558T (lt) 2012-03-13 2019-08-12 F. Hoffmann-La Roche Ag Derinių terapija, skirta kiaušidžių vėžiui gydyti
CN113234142B (zh) * 2012-08-22 2024-03-05 财团法人牧岩生命工学研究所 超稳定免疫球蛋白可变结构域的筛选和改造方法及其应用
WO2014055824A1 (en) 2012-10-05 2014-04-10 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease
KR101820699B1 (ko) 2012-11-01 2018-01-22 애브비 인코포레이티드 항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도
WO2014144280A2 (en) 2013-03-15 2014-09-18 Abbvie Inc. DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17
EP3933401A3 (en) 2013-03-27 2022-04-13 F. Hoffmann-La Roche AG Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
AR099856A1 (es) * 2014-03-27 2016-08-24 Genentech Inc Métodos para diagnosticar y tratar la enfermedad de intestino inflamado
EP3224280A1 (en) 2014-11-26 2017-10-04 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
CN107257693A (zh) * 2015-02-26 2017-10-17 豪夫迈·罗氏有限公司 治疗Crohn病的整联蛋白β7拮抗剂和方法
MA41636A (fr) 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
WO2017019673A2 (en) * 2015-07-27 2017-02-02 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease
JP2019512493A (ja) 2016-03-14 2019-05-16 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 移植片対宿主病の処置または予防の方法
MX2018011169A (es) 2016-03-14 2018-12-06 Millennium Pharm Inc Metodo para prevenir la enfermedad del injerto contra huesped.
JP7069032B2 (ja) 2016-03-24 2022-05-17 ミレニアム ファーマシューティカルズ， インコーポレイテッド がん免疫治療における胃腸の免疫関連有害事象の治療方法
TW201735949A (zh) 2016-03-24 2017-10-16 千禧製藥公司 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
PL3464318T3 (pl) 2016-06-02 2021-11-08 Abbvie Inc. Agonista receptora glukokortykoidowego i jego immunokoniugaty
WO2017218434A1 (en) 2016-06-12 2017-12-21 Millennium Pharmaceuticals, Inc. Method of treating inflammatory bowel disease
KR20190141148A (ko) 2017-04-28 2019-12-23 밀레니엄 파머슈티컬스 인코퍼레이티드 소아 장애를 치료하는 방법
KR20200095477A (ko) 2017-12-01 2020-08-10 애브비 인코포레이티드 글루코코르티코이드 수용체 작용제 및 이의 면역접합체
JP7365358B2 (ja) 2018-04-12 2023-10-19 モーフィック セラピューティック，インコーポレイテッド ヒトインテグリンα４β７のアンタゴニスト
WO2019236417A1 (en) 2018-06-04 2019-12-12 Biogen Ma Inc. Anti-vla-4 antibodies having reduced effector function
WO2020145669A1 (ko) * 2019-01-10 2020-07-16 에스지메디칼 주식회사 항 베타 1 인테그린 인간화 항체 및 이를 포함하는 암치료용 약학 조성물
PL439807A1 (pl) * 2019-06-10 2022-12-05 Takeda Pharmaceutical Company Limited Sposoby oczyszczania przeciwciał i ich kompozycje
WO2021076890A1 (en) 2019-10-16 2021-04-22 Morphic Therapeutic, Inc. INHIBITING HUMAN INTEGRIN α4β7
IL300133A (en) 2020-07-31 2023-03-01 Genentech Inc Anti-integrin antibody compositions in cell 7 and devices
WO2023086910A1 (en) 2021-11-12 2023-05-19 Genentech, Inc. Methods of treating crohn's disease using integrin beta7 antagonists

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
US4308428A (en) * 1979-12-26 1981-12-29 Cbs Inc. System for electronically simulating radiation effects produced by a rotary loudspeaker
US4331348A (en) * 1980-01-09 1982-05-25 Raidel John E Vehicle suspension
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4563304A (en) 1981-02-27 1986-01-07 Pharmacia Fine Chemicals Ab Pyridine compounds modifying proteins, polypeptides or polysaccharides
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5079233A (en) 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
US5508192A (en) 1990-11-09 1996-04-16 Board Of Regents, The University Of Texas System Bacterial host strains for producing proteolytically sensitive polypeptides
US5264365A (en) 1990-11-09 1993-11-23 Board Of Regents, The University Of Texas System Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
DE69233367T2 (de) 1991-04-10 2005-05-25 The Scripps Research Institute, La Jolla Bibliotheken heterodimerer rezeptoren mittels phagemiden
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
JP3951062B2 (ja) 1991-09-19 2007-08-01 ジェネンテック・インコーポレーテッド 少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、２官能性Ｆ（ａｂ’）２抗体の産生のための使用
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
US5362852A (en) 1991-09-27 1994-11-08 Pfizer Inc. Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
DE69329503T2 (de) 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
AU690528B2 (en) 1992-12-04 1998-04-30 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
US5610281A (en) 1994-05-03 1997-03-11 Brigham & Women's Hospital, Inc. Antibodies for modulating heterotypic E-cadherin interactions with human T lymphocytes
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5639635A (en) 1994-11-03 1997-06-17 Genentech, Inc. Process for bacterial production of polypeptides
AU4986296A (en) * 1995-02-10 1996-08-27 Leukosite Incorporated Mucosal vascular addressins and uses thereof
US6551593B1 (en) * 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US6027888A (en) 1996-04-05 2000-02-22 Board Of Regents, The University Of Texas System Methods for producing soluble, biologically-active disulfide-bond containing eukaryotic proteins in bacterial cells
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US6037454A (en) * 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US6083715A (en) 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
AU778050B2 (en) 1998-11-25 2004-11-11 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Antagonists of the alpha E beta 7 integrin as therapeutic agents for inflammatory diseases
AU2390400A (en) * 1999-01-08 2000-07-24 Brigham And Women's Hospital Methods and compositions for modulating cytokine release by alphaebeta7-expressing cells
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
JP4257210B2 (ja) * 2002-02-06 2009-04-22 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ パーソナルケア装置及び冷却装置を有するパーソナルケアシステム
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
NL1027975C2 (nl) 2004-01-09 2005-12-23 Pfizer Antilichamen tegen MAdCAM.
ATE452147T1 (de) * 2004-02-19 2010-01-15 Genentech Inc Antikörper mit korrigierten cdr
CN101094868B (zh) 2004-09-03 2013-07-10 健泰科生物技术公司 人源化的抗-β7拮抗剂及其应用
US10982250B2 (en) 2006-09-18 2021-04-20 Genentech, Inc. Methods of protein production
JP2007302676A (ja) 2007-05-29 2007-11-22 Genentech Inc ヒト化抗β７アンタゴニストおよびその使用

Also Published As

Publication number Publication date
US20170044261A1 (en) 2017-02-16
US20170210807A1 (en) 2017-07-27
RU2007112102A (ru) 2008-10-10
PL1784426T3 (pl) 2012-04-30
KR101364276B1 (ko) 2014-02-20
CN101094868A (zh) 2007-12-26
ES2377979T3 (es) 2012-04-03
HK1156955A1 (zh) 2012-06-22
NZ553328A (en) 2010-06-25
AU2005279720A1 (en) 2006-03-09
HK1221473A1 (zh) 2017-06-02
US20130288302A1 (en) 2013-10-31
PL3530673T3 (pl) 2022-08-01
IL226717A (en) 2016-04-21
EP3530673B1 (en) 2022-03-30
CY1112277T1 (el) 2015-12-09
EP1784426B1 (en) 2011-11-23
HUE039591T2 (hu) 2019-01-28
IL181473A (en) 2013-07-31
EP1784426A2 (en) 2007-05-16
BRPI0515602A (pt) 2008-07-29
DK2322556T3 (en) 2016-01-25
US7528236B2 (en) 2009-05-05
MX2007002675A (es) 2007-06-11
SI1784426T1 (sl) 2012-03-30
US8779100B2 (en) 2014-07-15
HRP20120171T1 (hr) 2012-03-31
US7687605B2 (en) 2010-03-30
SI2990422T1 (sl) 2018-10-30
JP2008512382A (ja) 2008-04-24
NO20171287A1 (no) 2007-06-01
RS52213B (en) 2012-10-31
NO342319B1 (no) 2018-05-07
US8124082B2 (en) 2012-02-28
SI3530673T1 (sl) 2022-08-31
PT2322556E (pt) 2016-02-15
PL2990422T3 (pl) 2018-11-30
JP5062887B2 (ja) 2012-10-31
PL2322556T3 (pl) 2016-04-29
ES2555355T3 (es) 2015-12-30
CA2577678A1 (en) 2006-03-09
ZA200701575B (en) 2008-09-25
IL244803B (en) 2018-02-28
EP3530673A1 (en) 2019-08-28
RS57636B1 (sr) 2018-11-30
US20060093601A1 (en) 2006-05-04
CY1117124T1 (el) 2017-04-05
WO2006026759A2 (en) 2006-03-09
LT3530673T (lt) 2022-06-10
AU2005279720B2 (en) 2011-07-28
NO342491B1 (no) 2018-06-04
HK1112002A1 (en) 2008-08-22
CN104710532B (zh) 2019-01-18
HK1210977A1 (en) 2016-05-13
CN103304667B (zh) 2015-04-08
IL244803A0 (en) 2016-04-21
HUE058817T2 (hu) 2022-09-28
NZ585628A (en) 2012-01-12
US20150197560A1 (en) 2015-07-16
US20200048354A1 (en) 2020-02-13
KR101433494B1 (ko) 2014-08-22
ES2690079T3 (es) 2018-11-19
EP2322556B1 (en) 2015-10-21
RS54409B1 (en) 2016-04-28
MX337423B (es) 2016-03-04
WO2006026759A3 (en) 2006-10-05
CN103304667A (zh) 2013-09-18
HRP20181459T1 (hr) 2018-10-19
US20080025971A1 (en) 2008-01-31
US20120208984A1 (en) 2012-08-16
DK1784426T3 (da) 2012-03-12
EP2990422A1 (en) 2016-03-02
NO341308B1 (no) 2017-10-02
KR20120115587A (ko) 2012-10-18
SI2322556T1 (sl) 2016-02-29
BRPI0515602B1 (pt) 2021-08-17
NO20171288A1 (no) 2007-06-01
CN104710532A (zh) 2015-06-17
EP2990422B1 (en) 2018-07-11
ATE534668T1 (de) 2011-12-15
CN101094868B (zh) 2013-07-10
US20180291104A1 (en) 2018-10-11
JP2012107050A (ja) 2012-06-07
DK3530673T3 (da) 2022-04-19
IL181473A0 (en) 2007-07-04
JP5255135B2 (ja) 2013-08-07
RU2453558C2 (ru) 2012-06-20
LT2990422T (lt) 2018-10-10
PT1784426E (pt) 2012-03-06
EP2322556A1 (en) 2011-05-18
HUE028441T2 (hu) 2016-12-28
NO20071740L (no) 2007-06-01
US20090226437A1 (en) 2009-09-10
US8835133B2 (en) 2014-09-16
PT2990422T (pt) 2018-10-18
ES2911482T3 (es) 2022-05-19
DK2990422T3 (en) 2018-09-17
IL226717A0 (en) 2013-07-31
HK1188798A1 (en) 2014-05-16
MX341370B (es) 2016-08-17
KR20070050986A (ko) 2007-05-16
CA2577678C (en) 2014-12-02
WO2006026759A9 (en) 2006-05-18

Similar Documents

Publication Publication Date Title
HRP20160034T1 (hr) Humanizirani antagonisti anti-beta7 i njihove uporabe
HRP20201993T1 (hr) Protutijela protiv pd-1
HRP20221141T1 (hr) Anti-lag3 protutijela
CN111108119B (zh) 新型抗CD3ε抗体
IL309975A (en) Antibodies against C5 and their uses
JP2020504101A5 (hr)
JP2017169559A5 (hr)
WO2019179388A1 (en) Novel anti-ctla-4 antibody polypeptide
JP2016520619A5 (hr)
JP2009523154A5 (hr)
HRP20201432T1 (hr) Il-17a sredstvo za vezivanje i njegove uporabe
HRP20151227T1 (hr) Sastavi i postupci uporabe za terapeutska protutijela
JP2015533795A5 (hr)
JP2020535799A5 (hr)
JP2016511277A5 (hr)
WO2005056600B1 (en) Monoclonal antibodies that bind or neutralize dengue virus
RU2011128399A (ru) Антитела к pd-l1 и их применение для усиления функции т-клеток
WO2008073312B1 (en) Urokinase-type plasminogen activator receptor epitope, monoclonal antibodies derived therefrom and methods of use thereof
NZ600512A (en) Neutralizing prolactin receptor antibodies and their therapeutic use
R Strohl Antibody discovery: sourcing of monoclonal antibody variable domains
JP2019516392A5 (hr)
RU2020127196A (ru) Антитело против 4-1bb, его антигенсвязывающий фрагмент и его медицинское применение
JP7438180B2 (ja) 新規抗ｌａｇ－３抗体ポリペプチド
CN115991778A (zh) 抗pd-l1抗体及其用途
PE20221447A1 (es) Anticuerpos anti-tgf-beta 1 latente y metodos de uso